EuroPCR 2022 | Galileo Trial: Mortality Predictors after Successful TAVR

Patients undergoing TAVR are mostly older and more fragile, with comorbidities both cardiovascular and non-cardiovascular.  Therefore, they are associated with thromboembolic and bleeding risk.

Galileo Trial: Predictores de mortalidad luego del implante exitoso del TAVI

This study looked mortality predictors after successful TAVR in the Galileo trial

Mortality at 248 days was 9.2%, 5.5% being of cardiovascular cause and 3.9% non-cardiovascular. 

Mortality predictors were age >85, male sex, hemoglobin <10 g/dL, COPD, peripheral vascular disease, eGFR <45 ml/min/1,73m2 and functional class III-IV.

The presence of thromboembolic events was 8.5%, with time to event 151 days, stroke being the most frequent followed by MI and less frequently symptomatic valve thrombosis, TVP, pulmonary embolism and systemic embolism. 

BARC bleeding was 18.2%, with time to first bleeding of 66 days, BARC 3 being most frequent, followed by 2, and less frequently 1 and 5.

Death after thromboembolism according to Kaplan Meier curve, reached 54.4% within a 36-day event to death time. 

Read also: EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

After BARC 2 or 3 bleeding, death was 17%, according to Kaplan Meier curve, within 178-day event to death time.

Bleedings BARC 2,3 and 5 were associated to mortality.

Authors have concluded that certain clinical variables are associated to mortality and that thromboembolic events are less frequent than bleeding, even though they are both associated to mortality (generally within a year). Moreover, they agree that the balance between bleeding event and thromboembolism after successful TAVR continues to be a challenge. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board in SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...